Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307458 | 0.88 | NPC1 (0.41) | NPC1RAB9AL3MBTL1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL6188607 | 0.86 | NPC1 (0.40) | NPC1RAB9AL3MBTL1HPGDSLC6A4 | |
| Hydrochloric Acid SCHEMBL6307331 | 0.86 | NPC1 (0.40) | NPC1RAB9AL3MBTL1HPGDSLC6A4 | |
| SCHEMBL31023988 | 0.74 | HTR2C (0.43) | TACR1SLC6A4SLC6A2 | |
| SCHEMBL31023847 | 0.74 | SLC6A4 (0.45) | NPC1RAB9ATRPM8TACR1SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL5040946 | 0.73 | SLC6A2 (0.35) | SLC6A4SLC6A2 | |
| SCHEMBL31023963 | 0.70 | CYP3A4 (0.43) | NPC1RAB9ASMN1; SMN2TACR1SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL7446778 | 0.69 | GABRP (0.39) | SLC6A4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL5443966 | 0.69 | GABRP (0.39) | SLC6A4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL5443972 | 0.69 | GABRP (0.39) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | NPC1 1922/4885RAB9A 1598/4885L3MBTL1 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.